Guzal R. Abuzarova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guzal R. Abuzarova has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Regina R. Sarmanayeva
P. A. Hertsen Moscow Oncology Research Institute – a branch of the National Medical Research Centre for Radiology of the Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia
18 shared publications - Galina S. Alekseeva
National Medical Research Radiological Centre
8 shared publications - S. V. Kuznetcov
P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Radiology Research Center, Ministry of Health of Russia
7 shared publications - Victoria E. Khoronenko
P.A. Hertsen Moscow Oncology Research Center, Moscow, Russia; RUDN University, Moscow, Russia
6 shared publications - Yu.V. Brazhnikova
P. Herzen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre
6 shared publications - Natalya M. Bychkova
Hertsen Moscow Scientific Researh Institute of Oncology – Branch of the National Medical Research Radiological Centre
5 shared publications
Latest Publications
- 15 October 2026
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 5
Opioid-sparing strategies for postoperative pain management in cancer patients with chronic pain syndrome undergoing spine fusion surgery
Postoperative analgesia in cancer patients with chronic pain syndrome (CPS) undergoing spine fusion surgery remains a complex clinical challenge due to multifactorial nature of pain and the risk of increased opioid burden. Objective. To summarize literature data on multimodal postoperative analgesia in cancer patients with emphasis on opioid-sparing approaches and infusion forms of non-steroidal anti-inflammatory drugs (NSAIDs). Material and methods. A narrative review with elements of systematic searching was performed using the PubMed and eLibrary databases. Results. Studies addressing CPS in malignant diseases, pain associated with metastatic spinal lesions and postoperative analgesia in spinal surgery including intravenous ibuprofen and a fixed combination of diclofenac with orphenadrine were analyzed. Literature data indicate that postoperative pain in these patients can include nociceptive, inflammatory, neuropathic, and muscle-tonic components. Conclusion. Infusion of NSAIDs is reasonable for multimodal opioid-sparing analgesic regimens. However, their efficacy and safety in cancer patients with CPS require further investigation.
- 15 October 2026
- Published by Media Sphere Publishing Group in Russian Journal of Anesthesiology and Reanimatology
- No. 5
Opioid-sparing strategies for postoperative pain management in cancer patients with chronic pain syndrome undergoing spine fusion surgery
Postoperative analgesia in cancer patients with chronic pain syndrome (CPS) undergoing spine fusion surgery remains a complex clinical challenge due to multifactorial nature of pain and the risk of increased opioid burden. Objective. To summarize literature data on multimodal postoperative analgesia in cancer patients with emphasis on opioid-sparing approaches and infusion forms of non-steroidal anti-inflammatory drugs (NSAIDs). Material and methods. A narrative review with elements of systematic searching was performed using the PubMed and eLibrary databases. Results. Studies addressing CPS in malignant diseases, pain associated with metastatic spinal lesions and postoperative analgesia in spinal surgery including intravenous ibuprofen and a fixed combination of diclofenac with orphenadrine were analyzed. Literature data indicate that postoperative pain in these patients can include nociceptive, inflammatory, neuropathic, and muscle-tonic components. Conclusion. Infusion of NSAIDs is reasonable for multimodal opioid-sparing analgesic regimens. However, their efficacy and safety in cancer patients with CPS require further investigation.
- 16 June 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (3) , 13-21
Efficacy and safety of Tafalgin in palliative patients with chronic pain: results of a multicenter NIKITA-P study
Objective. To evaluate the efficacy and safety of the peptide analgesic Tafalgin in palliative patients with chronic pain syndrome. Material and methods. A multicenter (19 centers) non-interventional clinical trial of NIKITA-Palliative was conducted in 188 patients, mainly with oncological (84.5%) chronic pain syndrome (CPS) and comorbid pathology. Results. The initial pain intensity (IP) was 7.18—8.11 NRS points (from 0 to 10), 15 minutes after injection there was a statistically significant decrease in pain at rest and during movement (p<0.0001); after 1 hour, IP decreased below the level of <3 points. Maximal analgesic effect was achieved after an average of 45 minutes, and the duration of anesthesia was 8.5 hours. The proportion of patients who responded to Tafalgin therapy was 94.1%, and 72.3% of patients achieved a sufficient level of anesthesia. During treatment, there was a statistically significant improvement in quality of life: a decrease in general weakness, irritability, daytime sleepiness, an improvement in nighttime sleep and appetite (p<0.0001), and an improvement in the quality of nighttime sleep. The majority of doctors (69.7%) and patients (66.6%) rated the effectiveness of Tafalgin therapy as good or excellent. Adverse reactions (AR) were reported in 14 of 188 patients (7.4%), with a total of 26 AR. The most common were blurred consciousness (2.6%), dizziness (2.1%) and dry mouth (1.6%). All AR were mild or moderate, no serious adverse reactions were recorded, and all episodes were treated without consequences. Conclusion. Tafalgin demonstrated an effective reduction in pain intensity lasting 8.5 hours against the background of a favorable safety profile in palliative patients with chronic pain syndrome despite concomitant pathology. The drug can be considered as an effective component of analgesic therapy of severe pain, including in combination with non-narcotic, narcotic and adjuvant analgesics.
- 16 June 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (3) , 13-21
Efficacy and safety of Tafalgin in palliative patients with chronic pain: results of a multicenter NIKITA-P study
Objective. To evaluate the efficacy and safety of the peptide analgesic Tafalgin in palliative patients with chronic pain syndrome. Material and methods. A multicenter (19 centers) non-interventional clinical trial of NIKITA-Palliative was conducted in 188 patients, mainly with oncological (84.5%) chronic pain syndrome (CPS) and comorbid pathology. Results. The initial pain intensity (IP) was 7.18—8.11 NRS points (from 0 to 10), 15 minutes after injection there was a statistically significant decrease in pain at rest and during movement (p<0.0001); after 1 hour, IP decreased below the level of <3 points. Maximal analgesic effect was achieved after an average of 45 minutes, and the duration of anesthesia was 8.5 hours. The proportion of patients who responded to Tafalgin therapy was 94.1%, and 72.3% of patients achieved a sufficient level of anesthesia. During treatment, there was a statistically significant improvement in quality of life: a decrease in general weakness, irritability, daytime sleepiness, an improvement in nighttime sleep and appetite (p<0.0001), and an improvement in the quality of nighttime sleep. The majority of doctors (69.7%) and patients (66.6%) rated the effectiveness of Tafalgin therapy as good or excellent. Adverse reactions (AR) were reported in 14 of 188 patients (7.4%), with a total of 26 AR. The most common were blurred consciousness (2.6%), dizziness (2.1%) and dry mouth (1.6%). All AR were mild or moderate, no serious adverse reactions were recorded, and all episodes were treated without consequences. Conclusion. Tafalgin demonstrated an effective reduction in pain intensity lasting 8.5 hours against the background of a favorable safety profile in palliative patients with chronic pain syndrome despite concomitant pathology. The drug can be considered as an effective component of analgesic therapy of severe pain, including in combination with non-narcotic, narcotic and adjuvant analgesics.
- Open Access
- 21 April 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 4,p. 68-76
Sublingual Bupraxon Tablets in Cancer Patients: Initial Results from Real-World Clinical Practice
Introduction. Adequate pain management in cancer patients remains a serious challenge. Long-term and uncontrolled use of NSAIDs is associated with a high risk of complications, while the use of opioids is often limited by their adverse effects, particularly constipation, and the potential risk of diversion. Combination drugs such as Bupraxon (buprenorphine + naloxone) represent a promising alternative.Objective. To present to the medical community the initial clinical experience with the domestic combined drug Bupraxon for sublingual administration in cancer patients with chronic pain syndrome (CPS).Methods and materials. This paper presents the results of a post-marketing observational study involving 22 cancer patients with CPS, as well as two detailed clinical case reports. The analgesic efficacy, time to onset and duration of action, tolerability, and safety of the drug were assessed in a real-world clinical setting.Results. Bupraxon was shown to provide effective control of moderate to severe intensity pain. The onset of action was observed within 30–45 minutes, and the duration of analgesia was 4–8 hours. For 12 out of 22 patients, an effective dose was titrated within 2–3 days. The drug was well-tolerated, with no significant gastrointestinal adverse events (specifically, no constipation) and no withdrawal syndrome following short-term use. The combination with naloxone enhances narcological safety by reducing the risk of abuse.Conclusions. Bupraxon is an effective and safe option for the management of CPS in cancer patients, particularly in those at risk of bowel obstruction. Its non-invasive form, controllable analgesia, and favorable safety profile make it a promising alternative to other opioid analgesics. Further comparative studies are required for a comprehensive assessment of the drug's potential.
- 21 April 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 4,p. 68-76
Open AccessSublingual Bupraxon Tablets in Cancer Patients: Initial Results from Real-World Clinical Practice
Introduction. Adequate pain management in cancer patients remains a serious challenge. Long-term and uncontrolled use of NSAIDs is associated with a high risk of complications, while the use of opioids is often limited by their adverse effects, particularly constipation, and the potential risk of diversion. Combination drugs such as Bupraxon (buprenorphine + naloxone) represent a promising alternative.Objective. To present to the medical community the initial clinical experience with the domestic combined drug Bupraxon for sublingual administration in cancer patients with chronic pain syndrome (CPS).Methods and materials. This paper presents the results of a post-marketing observational study involving 22 cancer patients with CPS, as well as two detailed clinical case reports. The analgesic efficacy, time to onset and duration of action, tolerability, and safety of the drug were assessed in a real-world clinical setting.Results. Bupraxon was shown to provide effective control of moderate to severe intensity pain. The onset of action was observed within 30–45 minutes, and the duration of analgesia was 4–8 hours. For 12 out of 22 patients, an effective dose was titrated within 2–3 days. The drug was well-tolerated, with no significant gastrointestinal adverse events (specifically, no constipation) and no withdrawal syndrome following short-term use. The combination with naloxone enhances narcological safety by reducing the risk of abuse.Conclusions. Bupraxon is an effective and safe option for the management of CPS in cancer patients, particularly in those at risk of bowel obstruction. Its non-invasive form, controllable analgesia, and favorable safety profile make it a promising alternative to other opioid analgesics. Further comparative studies are required for a comprehensive assessment of the drug's potential.
- 29 October 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (5) , 73-77
New analgesics in oncology. Tafalgin employed as an alternative to opioid analgesics
The publication presents data on new analgesics that could serve as an alternative to opioids, having a comparable analgesic effect, but with a lower risk of serious adverse events. Tafalgin is a selective agonist of the m1-opioid receptors, due to which it has a decend analgetic effect comparable to opioid analgesics with a more favorable safety profile, which has been demonstrated both in clinical studies and in real clinical practice. Tafalgin has been introduced into clinical practice relatively recently, so there are few publications revealing the specifics of its use in various clinical situations. The presented clinical observation describes the possibility of taking Tafalgin not only as a drug for the treatment of acute or breakthrough pain, but also as a basic analgesic for intensity pain syndromes, especially in situations where taking opioid analgesics is undesirable or impossible for any reason.
- 29 October 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (5) , 73-77
New analgesics in oncology. Tafalgin employed as an alternative to opioid analgesics
The publication presents data on new analgesics that could serve as an alternative to opioids, having a comparable analgesic effect, but with a lower risk of serious adverse events. Tafalgin is a selective agonist of the m1-opioid receptors, due to which it has a decend analgetic effect comparable to opioid analgesics with a more favorable safety profile, which has been demonstrated both in clinical studies and in real clinical practice. Tafalgin has been introduced into clinical practice relatively recently, so there are few publications revealing the specifics of its use in various clinical situations. The presented clinical observation describes the possibility of taking Tafalgin not only as a drug for the treatment of acute or breakthrough pain, but also as a basic analgesic for intensity pain syndromes, especially in situations where taking opioid analgesics is undesirable or impossible for any reason.
- 25 December 2024
- Published by ECO-Vector LLC in Regional Anesthesia and Acute Pain Management
- Vol. 18 (4) , 356-372
Experience with an opioid peptide (tyrosyl-D-arginyl-phenylalanyl-glycine amide) in oncology: a comparative randomized clinical study
Background: The application of tyrosyl-D-arginyl-phenylalanyl-glycine amide, a highly specific μ1-opioid receptor agonist, represents a promising approach for managing acute postoperative pain. Aim: To evaluate the efficacy and safety of tyrosyl-D-arginyl-phenylalanyl-glycine amide in oncology patients, depending on the type of anesthesia used for various surgical interventions. Materials and methods: A comparative randomized clinical study included 80 patients aged 29–86 years [median age (Me) 66 years, interquartile range (Q1; Q3) 59–71 years], of whom 46 (57.5%) were men and 34 (42.5%) were women, classified as American Society of Anesthesiologists (ASA) physical status I–III. These patients underwent planned surgical treatment for oncological diseases. Patients received either multimodal combined general anesthesia with mechanical ventilation in the control group (Group K, n=40) or combined anesthesia (general+epidural/intercostal block for thoracic surgeries) in the comparison group (Group C, n=40). All patients were administered a standardized postoperative systemic analgesia protocol based on tyrosyl-D-arginyl-phenylalanyl-glycine amide at a dose of 4 mg 3 times per day. The first dose was administered when pain intensity exceeded 3 points at rest and 4 points during movement on the Numeric Rating Scale (NRS). Pain intensity was assessed at rest and during movement at predetermined time points: 15, 30, 45, 60, 120, and 240 minutes after the first dose. Results: Baseline pain intensity at rest (NRS) was higher in Group K compared to Group C [Me=6, (Q1; Q3)=(5; 5) and (5; 6), respectively; p=0.038]. While initial pain intensity during movement was similar between groups (Me=7 points), the interquartile range was greater in Group K [(Q1; Q3) = (6; 8)] compared to Group C [(6; 7); p=0.045]. Lower pain scores were observed in Group C at 45 and 60 minutes at rest (p=0.005 and p=0.008, respectively) and at 30 minutes during movement (p=0.036). Conclusion: The combination of tyrosyl-D-arginyl-phenylalanyl-glycine amide with regional perioperative blocks is an optimal method for managing acute pain in the early postoperative period for patients undergoing complex and traumatic oncological surgeries.
- 25 December 2024
- Published by ECO-Vector LLC in Regional Anesthesia and Acute Pain Management
- Vol. 18 (4) , 356-372
Experience with an opioid peptide (tyrosyl-D-arginyl-phenylalanyl-glycine amide) in oncology: a comparative randomized clinical study
Background: The application of tyrosyl-D-arginyl-phenylalanyl-glycine amide, a highly specific μ1-opioid receptor agonist, represents a promising approach for managing acute postoperative pain. Aim: To evaluate the efficacy and safety of tyrosyl-D-arginyl-phenylalanyl-glycine amide in oncology patients, depending on the type of anesthesia used for various surgical interventions. Materials and methods: A comparative randomized clinical study included 80 patients aged 29–86 years [median age (Me) 66 years, interquartile range (Q1; Q3) 59–71 years], of whom 46 (57.5%) were men and 34 (42.5%) were women, classified as American Society of Anesthesiologists (ASA) physical status I–III. These patients underwent planned surgical treatment for oncological diseases. Patients received either multimodal combined general anesthesia with mechanical ventilation in the control group (Group K, n=40) or combined anesthesia (general+epidural/intercostal block for thoracic surgeries) in the comparison group (Group C, n=40). All patients were administered a standardized postoperative systemic analgesia protocol based on tyrosyl-D-arginyl-phenylalanyl-glycine amide at a dose of 4 mg 3 times per day. The first dose was administered when pain intensity exceeded 3 points at rest and 4 points during movement on the Numeric Rating Scale (NRS). Pain intensity was assessed at rest and during movement at predetermined time points: 15, 30, 45, 60, 120, and 240 minutes after the first dose. Results: Baseline pain intensity at rest (NRS) was higher in Group K compared to Group C [Me=6, (Q1; Q3)=(5; 5) and (5; 6), respectively; p=0.038]. While initial pain intensity during movement was similar between groups (Me=7 points), the interquartile range was greater in Group K [(Q1; Q3) = (6; 8)] compared to Group C [(6; 7); p=0.045]. Lower pain scores were observed in Group C at 45 and 60 minutes at rest (p=0.005 and p=0.008, respectively) and at 30 minutes during movement (p=0.036). Conclusion: The combination of tyrosyl-D-arginyl-phenylalanyl-glycine amide with regional perioperative blocks is an optimal method for managing acute pain in the early postoperative period for patients undergoing complex and traumatic oncological surgeries.
- Open Access
- 18 December 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (3) , 65-78
Acute pain in oncology: specific features and treatment options. What is new?
Background: Cancer patients experience acute pain at various the stages of antitumor therapy, which can reduce the patient's commitment to treatment and trust in the doctor, therefore, rapid relief of acute pain is very important. Objective: The aims of the article is to describe the options for acute pain relief in oncology, to characterize the main groups of analgetics, to present data of clinical trials and clinical cases of the use of Tafalgin — the new generation drug from the group of central analgesics.Methods: Analysis of the literature on pain therapy in cancer therapy, and own data within the framework of the multicenter study “Observational program for monitoring the effectiveness and safety of Tafalgin® in real clinical practice — NIKITA”.Results: The classification of acute pain in cancer patients in cancer therapy is proposed, analgesics and the features of their use depending on the intensity of pain are described. The results of Tafalgin use show that in 15 minutes after its subcutaneous administration there was a decrease in the intensity of pain by 59.6 %. The duration of analgesia reached 9.35 ± 6.3 hours. An acceptable level of pain relief was achieved in 84 % of patients. 19 mild and moderate adverse events were detected in 15 patients.Conclusion: Acute pain in cancer patients continues to be a problem, despite the large number of analgesics, so the introduction into clinical practice of a new effective analgesic Tafalgin might ensure pain control.
- 18 December 2024
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (3) , 65-78
Open AccessAcute pain in oncology: specific features and treatment options. What is new?
Background: Cancer patients experience acute pain at various the stages of antitumor therapy, which can reduce the patient's commitment to treatment and trust in the doctor, therefore, rapid relief of acute pain is very important. Objective: The aims of the article is to describe the options for acute pain relief in oncology, to characterize the main groups of analgetics, to present data of clinical trials and clinical cases of the use of Tafalgin — the new generation drug from the group of central analgesics.Methods: Analysis of the literature on pain therapy in cancer therapy, and own data within the framework of the multicenter study “Observational program for monitoring the effectiveness and safety of Tafalgin® in real clinical practice — NIKITA”.Results: The classification of acute pain in cancer patients in cancer therapy is proposed, analgesics and the features of their use depending on the intensity of pain are described. The results of Tafalgin use show that in 15 minutes after its subcutaneous administration there was a decrease in the intensity of pain by 59.6 %. The duration of analgesia reached 9.35 ± 6.3 hours. An acceptable level of pain relief was achieved in 84 % of patients. 19 mild and moderate adverse events were detected in 15 patients.Conclusion: Acute pain in cancer patients continues to be a problem, despite the large number of analgesics, so the introduction into clinical practice of a new effective analgesic Tafalgin might ensure pain control.
- Open Access
- 1 August 2024
- Published by ECO-Vector LLC in Regional Anesthesia and Acute Pain Management
- Vol. 18 (2) , 115-131
Potential of modern nonopioid analgesics in the prevention and treatment of pain syndrome in decompressive stabilizing spine surgeries
BACKGROUND: Secondary (tumor) lesion of the spine in 80% of cases is accompanied by chronic pain syndrome (CPS). A decrease in opioid subsidies in the postoperative period is important not only to prevent side effects, but also in order to create a reserve when providing palliative care for patients with CP, due to the pathology of the skeletal muscle system. AIM: To optimize postop analgesia for cancer patients with CPS undergoing decompressive-stabilizing spine surgery. MATERIALS AND METHODS: We included 52 patients aged 32–76 (average age: 59±10 [95% CI: 56–62]) years, 23 (44.2%) men and 29 (55.8%) women, with physical status according to the classification of patients of the American Society of Anesthesiologists I–III, CPS without therapy were included strong opioids for spinal metastases. Patients were randomized according to the type of postop analgesia: tramadol was used in the control group (group K) (n=15, 28.8%), a combination of diclofenac and orphenadrine in group D (n=18, 34.6%), and ibuprofen in group I (n=19, 36.5%). Postoperative pain intensity deduced using the visual analog scale was determined during extubation, transfer to a bed in the intensive care unit, 1 and 3 hours postop, and 21:00 on the day of surgery and 06:00 on day 2. The effect duration of the analgesic under study, the need for anesthesia on the postop day, and satisfaction with Likert anesthesia 1 hour after administration were evaluated. RESULTS: Significant differences in the average values of pain intensity at rest at 06:00 on postoperative day 2 between groups D (Me=10) and K (Me=20) were obtained. Satisfaction with pain relief according to Likert scale in the groups was rated “excellent” or “good.” The duration of opioid therapy was significantly lower in the nonopioid groups (six postop days in groups I and D versus seven in group K; p=0.013). CONCLUSIONS: Postop analgesia methods using nonopioid analgesics are effective and possess opioid-sparing potential.
- 1 August 2024
- Published by ECO-Vector LLC in Regional Anesthesia and Acute Pain Management
- Vol. 18 (2) , 115-131
Open AccessPotential of modern nonopioid analgesics in the prevention and treatment of pain syndrome in decompressive stabilizing spine surgeries
BACKGROUND: Secondary (tumor) lesion of the spine in 80% of cases is accompanied by chronic pain syndrome (CPS). A decrease in opioid subsidies in the postoperative period is important not only to prevent side effects, but also in order to create a reserve when providing palliative care for patients with CP, due to the pathology of the skeletal muscle system. AIM: To optimize postop analgesia for cancer patients with CPS undergoing decompressive-stabilizing spine surgery. MATERIALS AND METHODS: We included 52 patients aged 32–76 (average age: 59±10 [95% CI: 56–62]) years, 23 (44.2%) men and 29 (55.8%) women, with physical status according to the classification of patients of the American Society of Anesthesiologists I–III, CPS without therapy were included strong opioids for spinal metastases. Patients were randomized according to the type of postop analgesia: tramadol was used in the control group (group K) (n=15, 28.8%), a combination of diclofenac and orphenadrine in group D (n=18, 34.6%), and ibuprofen in group I (n=19, 36.5%). Postoperative pain intensity deduced using the visual analog scale was determined during extubation, transfer to a bed in the intensive care unit, 1 and 3 hours postop, and 21:00 on the day of surgery and 06:00 on day 2. The effect duration of the analgesic under study, the need for anesthesia on the postop day, and satisfaction with Likert anesthesia 1 hour after administration were evaluated. RESULTS: Significant differences in the average values of pain intensity at rest at 06:00 on postoperative day 2 between groups D (Me=10) and K (Me=20) were obtained. Satisfaction with pain relief according to Likert scale in the groups was rated “excellent” or “good.” The duration of opioid therapy was significantly lower in the nonopioid groups (six postop days in groups I and D versus seven in group K; p=0.013). CONCLUSIONS: Postop analgesia methods using nonopioid analgesics are effective and possess opioid-sparing potential.
- 23 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (6)
Use of a new tetrapeptide analgesic at the stages of antitumor therapy
Objective. To present the interim results of the Observational Program for monitoring the effectiveness and safety of Tafalgin in real clinical practice “NIKITA” in a group of patients receiving anticancer treatment. Material and methods. The analysis of intermediate data in separate groups of patients receiving radiation therapy and chemotherapy (RT and ChT) was carried out. The proportion of patients who responded to therapy after the first injection of Tafalgin was revealed, the analgesic effect of Tafalgin was assessed: the average time of onset and duration of analgesia, the effectiveness of anesthesia on a 10-point numerological evaluation scale (NRS); assessment of the dynamics of physical activity on the ECOG scale, the quality of night sleep, assessment of doctor satisfaction and safety of Tafalgin. Results. In the RT group, there was a statistically significant decrease in pain intensity to 3.2±2.0 on the NRS (p<0.001) 15 min. after subcutaneous injection 4 mg of Tafalgin and — 2.0± 1.5 after 1 hour. The median time to achieve the maximum analgesic effect was 13.5 (10; 30) min., and the median time to maintain the achieved analgesic effect was 360 (300; 660) min. The proportion of patients with an acceptable level of pain relief was achieved in 85% of patients. In the ChT group maximum analgesic effect was 2.4±1.7 after injection, the median time to achieve the maximum effect was 40 (30; 60) min., and to maintain the achieved analgesic effect was 240 (180; 420) min. The proportion of patients with an acceptable level of analgesia was 72.9% of patients. Side effects prevailed in ChT group and were detected in 38.9%, in the in RT group it was 15%. Severity of side effects were mild or moderate, resolved independently within 30—60 minutes. Satisfaction with the analgesic effect of Tafalgin was high in patients of both groups and in research physicians. Conclusion. Tafalgin has a strong analgesic efficiency and an acceptable security profile. Tafalgin may be recommended for use in broad clinical practice in oncology in radiation and drug therapy.
- 23 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (6)
Use of a new tetrapeptide analgesic at the stages of antitumor therapy
Objective. To present the interim results of the Observational Program for monitoring the effectiveness and safety of Tafalgin in real clinical practice “NIKITA” in a group of patients receiving anticancer treatment. Material and methods. The analysis of intermediate data in separate groups of patients receiving radiation therapy and chemotherapy (RT and ChT) was carried out. The proportion of patients who responded to therapy after the first injection of Tafalgin was revealed, the analgesic effect of Tafalgin was assessed: the average time of onset and duration of analgesia, the effectiveness of anesthesia on a 10-point numerological evaluation scale (NRS); assessment of the dynamics of physical activity on the ECOG scale, the quality of night sleep, assessment of doctor satisfaction and safety of Tafalgin. Results. In the RT group, there was a statistically significant decrease in pain intensity to 3.2±2.0 on the NRS (p<0.001) 15 min. after subcutaneous injection 4 mg of Tafalgin and — 2.0± 1.5 after 1 hour. The median time to achieve the maximum analgesic effect was 13.5 (10; 30) min., and the median time to maintain the achieved analgesic effect was 360 (300; 660) min. The proportion of patients with an acceptable level of pain relief was achieved in 85% of patients. In the ChT group maximum analgesic effect was 2.4±1.7 after injection, the median time to achieve the maximum effect was 40 (30; 60) min., and to maintain the achieved analgesic effect was 240 (180; 420) min. The proportion of patients with an acceptable level of analgesia was 72.9% of patients. Side effects prevailed in ChT group and were detected in 38.9%, in the in RT group it was 15%. Severity of side effects were mild or moderate, resolved independently within 30—60 minutes. Satisfaction with the analgesic effect of Tafalgin was high in patients of both groups and in research physicians. Conclusion. Tafalgin has a strong analgesic efficiency and an acceptable security profile. Tafalgin may be recommended for use in broad clinical practice in oncology in radiation and drug therapy.
- 23 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (5)
Unresolved problem: Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a significant problem in oncology, which greatly worsens the quality of life of patients and is the reason for the reduction or cancellation of cancer therapy. The review presents the pathophysiological features of the development of CIPN, describes the features of the diagnosis of CIPN, risk factors for its development, prevention and treatment. In addition to the only currently approved ASCO duloxetine, the results of clinical studies confirming the therapeutic effect of a central analgesic with a mixed mechanism of action, tapentadol, comparable to duloxetine, are presented
- 23 April 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (5)
Unresolved problem: Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a significant problem in oncology, which greatly worsens the quality of life of patients and is the reason for the reduction or cancellation of cancer therapy. The review presents the pathophysiological features of the development of CIPN, describes the features of the diagnosis of CIPN, risk factors for its development, prevention and treatment. In addition to the only currently approved ASCO duloxetine, the results of clinical studies confirming the therapeutic effect of a central analgesic with a mixed mechanism of action, tapentadol, comparable to duloxetine, are presented
- Open Access
- 11 December 2023
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 13 (3) , 43-50
Orofacial pain in oncology: use of a new analgesic peptide tafalgin
In patients with head and neck tumors severe pain is more common than in patients with malignant neoplasms of other locations. At a third of patients, pain is the first characteristic of the disease, and after diagnosis, one half of the patients are already having pain syndrome. Аntitumor treatment often not only bring relief, but can intensify pain, which can reduce wish to treated. Part of cancer survivor continue to experience. Thus, orofacial pain syndrome should be share depending on the mechanism of appearence and tactics of treatment on three periods: pain at the stage of diagnosis, then pain syndrome in process antitumor therapy and pain in remission. It is actually if it necessary to prescribe opioid analgesics, especially for a long time. Intensity of orofacial pain syndrome is usually strong and often need to prescribe opioid analgesics. Option to opioid analgesics may be a representative of a new group of analgetics – peptide analgesics – tafalgin. The mechanism of action is due to highly selective agonism to the m1-opioid receptors. The presented clinical example demonstrates the good analgesic effect of tafalgin and the possibility use as option to analgesics of the second stage of pain management.
- 11 December 2023
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 13 (3) , 43-50
Open AccessOrofacial pain in oncology: use of a new analgesic peptide tafalgin
In patients with head and neck tumors severe pain is more common than in patients with malignant neoplasms of other locations. At a third of patients, pain is the first characteristic of the disease, and after diagnosis, one half of the patients are already having pain syndrome. Аntitumor treatment often not only bring relief, but can intensify pain, which can reduce wish to treated. Part of cancer survivor continue to experience. Thus, orofacial pain syndrome should be share depending on the mechanism of appearence and tactics of treatment on three periods: pain at the stage of diagnosis, then pain syndrome in process antitumor therapy and pain in remission. It is actually if it necessary to prescribe opioid analgesics, especially for a long time. Intensity of orofacial pain syndrome is usually strong and often need to prescribe opioid analgesics. Option to opioid analgesics may be a representative of a new group of analgetics – peptide analgesics – tafalgin. The mechanism of action is due to highly selective agonism to the m1-opioid receptors. The presented clinical example demonstrates the good analgesic effect of tafalgin and the possibility use as option to analgesics of the second stage of pain management.